Eton Pharmaceuticals Inc. (ETON) is carving out a strong position in rare disease care, building a fast-growing portfolio of treatments backed by a consistent track record of successful commercialization.
The company has 10 commercial products - INCRELEX for Severe Primary Insulin-Like Growth Factor 1 Deficiency; ALKINDI SPRINKLE for Pediatric Adrenal Insufficiency; KHINDIVI for Pediatric Adrenal Insufficiency; GALZIN for Wilson disease; PKU GOLIKE for Phenylketonuria; Carglumic Acid for Hyperammonemia; Betaine Anhydrous for Homocystinuria; DESMODA for Diabetes Insipidus; HEMANGEOL for Infantile Hemangioma; and Nitisinone for Hereditary Tyrosinemia Type 1 (HT-1).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.